Key terms
About ITOS
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ITOS news
Apr 07
4:51pm ET
iTeos Therapeutics presents preclinical data on EOS-984
Mar 21
7:30am ET
Analysts Offer Insights on Healthcare Companies: iTeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)
Mar 12
5:03pm ET
iTeos Therapeutics management to meet with Piper Sandler
Mar 12
6:40am ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), AnaptysBio (ANAB) and iTeos Therapeutics (ITOS)
Mar 11
12:50am ET
Analysts Are Bullish on These Healthcare Stocks: iTeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)
Mar 07
6:30am ET
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), iTeos Therapeutics (ITOS) and Rezolute (RZLT)
Mar 06
7:05am ET
iTeos Therapeutics reports Q4 EPS (85c), consensus ($1.03)
Mar 06
7:05am ET
iTeos Therapeutics appoints DeSimone to board of directors
No recent press releases are available for ITOS
ITOS Financials
Key terms
Ad Feedback
ITOS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ITOS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
